Point72 Asset Management
CRSP icon

Point72 Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Point72 Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25M Sell
26,300
-7,400
-22% -$390K ﹤0.01% 2611
2025
Q4 		$1.77M Buy
+33,700
New +$2.02M ﹤0.01% 2552
2025
Q2 		– Sell
-100,000
Closed -$3.4M – 2259
2025
Q1 		$3.4M Buy
+100,000
New +$4.24M 0.01% 1078

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management's CRSP Position: Q4 2019 in Review

Point72 Asset Management sold out of CRISPR Therapeutics (CRSP) in Q4 2019, closing a stake of 6,456 shares — an estimated $265K sold.

Point72 Asset Management first reported a position in CRSP in Q1 2019 and held it in 3 quarters. The position peaked at $332K in Q2 2019. 253 funds tracked by Wall St. Rank hold CRSP as of Q4 2019.

  • Point72 Asset Management reported no remaining CRISPR Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Point72 Asset Management sold 6,456 CRISPR Therapeutics shares in Q4 2019, an estimated $265K.
  • Point72 Asset Management first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 3 quarters.
  • Point72 Asset Management's CRISPR Therapeutics position peaked at $332K in Q2 2019.
  • 253 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2019.

Based on Point72 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.